Sun et al. revealed that tucidinostat is effective in MM treatment through regulating levels of H3K27ac to increase the transcription of succinate dehydrogenase subunit A (SDHA), which is proven to be a potential prognostic factor of MM patients (Sun et al., 2020). The gene discussed is SDHA; the disease is Miyoshi myopathy.